Literature DB >> 22409770

Conference highlights of the 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin, West Indies.

Mario Stevenson1, Nicolas Chomont2, Alain Lafeuillade3.   

Abstract

The December 2011 5th International Workshop on HIV Persistence during Therapy addressed the issue of HIV persistence among 210 scientists from 10 countries involved in the study of HIV reservoirs and the search of an HIV cure. High quality abstracts were selected and discussed as oral or poster presentations. The aim of this review is to distribute the scientific highlights of this workshop outside the group as analyzed and represented by experts in retrovirology, immunology and clinical research.

Entities:  

Year:  2012        PMID: 22409770      PMCID: PMC3338393          DOI: 10.1186/1742-6405-9-7

Source DB:  PubMed          Journal:  AIDS Res Ther        ISSN: 1742-6405            Impact factor:   2.250


  19 in total

1.  Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.

Authors:  Matthew C Strain; Susan J Little; Eric S Daar; Diane V Havlir; Huldrych F Gunthard; Ruby Y Lam; Otto A Daly; Juin Nguyen; Caroline C Ignacio; Celsa A Spina; Douglas D Richman; Joseph K Wong
Journal:  J Infect Dis       Date:  2005-03-29       Impact factor: 5.226

Review 2.  HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals.

Authors:  Didier Trono; Carine Van Lint; Christine Rouzioux; Eric Verdin; Françoise Barré-Sinoussi; Tae-Wook Chun; Nicolas Chomont
Journal:  Science       Date:  2010-07-09       Impact factor: 47.728

3.  Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir.

Authors:  F Lori; H Jessen; J Lieberman; D Finzi; E Rosenberg; C Tinelli; B Walker; R F Siliciano; J Lisziewicz
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

4.  Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy.

Authors:  Alex Sigal; Jocelyn T Kim; Alejandro B Balazs; Erez Dekel; Avi Mayo; Ron Milo; David Baltimore
Journal:  Nature       Date:  2011-08-17       Impact factor: 49.962

5.  SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx.

Authors:  Nadine Laguette; Bijan Sobhian; Nicoletta Casartelli; Mathieu Ringeard; Christine Chable-Bessia; Emmanuel Ségéral; Ahmad Yatim; Stéphane Emiliani; Olivier Schwartz; Monsef Benkirane
Journal:  Nature       Date:  2011-05-25       Impact factor: 49.962

6.  Activation of latent HIV using drug-loaded nanoparticles.

Authors:  Michael Kovochich; Matthew D Marsden; Jerome A Zack
Journal:  PLoS One       Date:  2011-04-05       Impact factor: 3.240

7.  Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART.

Authors:  Erin H Graf; Angela M Mexas; Jianqing J Yu; Farida Shaheen; Megan K Liszewski; Michele Di Mascio; Stephen A Migueles; Mark Connors; Una O'Doherty
Journal:  PLoS Pathog       Date:  2011-02-24       Impact factor: 6.823

8.  Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein.

Authors:  Kasia Hrecka; Caili Hao; Magda Gierszewska; Selene K Swanson; Malgorzata Kesik-Brodacka; Smita Srivastava; Laurence Florens; Michael P Washburn; Jacek Skowronski
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

9.  Picomolar dichotomous activity of gnidimacrin against HIV-1.

Authors:  Li Huang; Phong Ho; Jie Yu; Lei Zhu; Kuo-Hsiung Lee; Chin-Ho Chen
Journal:  PLoS One       Date:  2011-10-24       Impact factor: 3.240

10.  "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence.

Authors:  Andrea Savarino; Antonello Mai; Sandro Norelli; Sary El Daker; Sergio Valente; Dante Rotili; Lucia Altucci; Anna Teresa Palamara; Enrico Garaci
Journal:  Retrovirology       Date:  2009-06-02       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.